An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
Secondary chromosomal changes are known to develop in Philadelphia chromosome-negative (Ph-) cells of chronic myelogenous leukemia (CML) patients after treatment with imatinib mesylate, an ABL kinase inhibitor. We report here a novel case of a pericentric inversion of chromosome 16 as the sole cytogenetic abnormality in Ph- cells after treatment of Ph+ CML with imatinib.
Rowe
Leslie R
LR
Institute for Clinical and Experimental Pathology, Associated Regional and University Pathologists (ARUP) Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108-1221, USA. rowelr@aruplab.com
Brothman
Arthur R
AR
Nibley
William E
WE
Gaffney
Michael R
MR
Chen
Zhong
Z
D000368:Aged; D001549:Benzamides; D007446:Chromosome Inversion / Q000235:genetics*; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D050658:Core Binding Factor beta Subunit / Q000378:metabolism; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; C493692:CBFB protein, human; D050658:Core Binding Factor beta Subunit; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate